Ramirez Asset Management Inc. Lowers Stock Holdings in Natera, Inc. $NTRA

Ramirez Asset Management Inc. reduced its stake in Natera, Inc. (NASDAQ:NTRA) by 25.0% during the 2nd quarter, HoldingsChannel reports. The firm owned 300 shares of the medical research company’s stock after selling 100 shares during the period. Ramirez Asset Management Inc.’s holdings in Natera were worth $51,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of NTRA. Price T Rowe Associates Inc. MD grew its stake in shares of Natera by 56.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock valued at $1,490,144,000 after purchasing an additional 3,795,315 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Natera in the 1st quarter valued at approximately $113,375,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Natera by 140.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company’s stock valued at $177,298,000 after buying an additional 732,156 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Natera by 9.9% in the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company’s stock valued at $1,041,055,000 after buying an additional 660,538 shares during the period. Finally, Ninety One UK Ltd lifted its holdings in shares of Natera by 149.1% in the 2nd quarter. Ninety One UK Ltd now owns 562,985 shares of the medical research company’s stock valued at $95,111,000 after buying an additional 336,985 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Natera news, CFO Michael Burkes Brophy sold 3,045 shares of the firm’s stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total transaction of $418,383.00. Following the completion of the transaction, the chief financial officer owned 65,430 shares of the company’s stock, valued at approximately $8,990,082. This trade represents a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction on Friday, August 1st. The shares were sold at an average price of $132.89, for a total value of $398,670.00. Following the completion of the sale, the insider directly owned 123,059 shares of the company’s stock, valued at approximately $16,353,310.51. This represents a 2.38% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 72,464 shares of company stock worth $10,963,125. 5.63% of the stock is currently owned by corporate insiders.

Natera Stock Performance

Shares of NTRA stock opened at $169.27 on Friday. The stock has a fifty day moving average price of $164.58 and a 200 day moving average price of $157.22. The stock has a market cap of $23.23 billion, a PE ratio of -88.62 and a beta of 1.74. Natera, Inc. has a 1 year low of $117.27 and a 1 year high of $183.00.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The firm had revenue of $546.60 million for the quarter, compared to analyst estimates of $476.84 million. Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business’s revenue for the quarter was up 32.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on NTRA shares. Piper Sandler reissued an “overweight” rating and issued a $220.00 price target (up from $210.00) on shares of Natera in a report on Monday, August 11th. Royal Bank Of Canada set a $268.00 price target on Natera and gave the company an “outperform” rating in a report on Tuesday, September 2nd. Stephens reissued an “overweight” rating and issued a $183.00 price target on shares of Natera in a report on Friday, August 15th. Cowen reissued a “buy” rating on shares of Natera in a report on Friday, August 8th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $195.00 price target on shares of Natera in a report on Sunday, August 10th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and an average target price of $192.88.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.